This Monday was the third full day of the American Society of Hematology 2010 annual meeting, and it was packed with multiple myeloma-related presentations.  The Beacon published an update earlier today covering presentations made Monday morning.  This article covers material from Monday afternoon and evening.

The first presentation of the afternoon was by Dr. Ruben Niesvizky of the Weill Cornell Medical College in New York.  He reported on the results of a Phase 3 trial using Velcade (bor­tez­o­mib)-based initial treat­ment (induction) regi­mens com­bined with …

Monday was the third full day of “ASH 2010,” this year’s annual meeting of the American Society of Hematology.  This day was the busiest of the entire meeting in terms of multiple myeloma-related material.  Presentations summarizing the latest myeloma research stretched from 7 a.m. until 8 p.m.

The morning presentations from Monday will be covered in this update, and presentations from the afternoon and evening will be covered in another update later today.

The day featured a large number of …

Yesterday was the second full day of the 2010 American Society of Hematology annual meeting in Orlando. It was a particularly busy day in terms of material related to multiple myeloma, with numerous oral presentations during the day and an extensive poster session in the early evening.

One of the first presentations of the day was actually a press conference held to review the results of a Phase 3 study comparing the efficacy and safety of two different stem cell …

There are probably few words more frightening than those of a doctor telling you "I'm sorry, but I'm afraid you have cancer."

Those words are even more frightening when you're told the cancer you have is one you've never heard of.

You can imagine, then, how tens of thousands of men and women around the world feel each year when they learn they have multiple myeloma.

They are told they have cancer. Multiple myeloma, to be specific. And it's a …